S1PR1 (Sphingosine-1-Phosphate Receptor 1) Protein

S1PR1 (Sphingosine-1-Phosphate Receptor 1) Protein

<div class="infobox infobox-protein">
| | |
|---|---|
| Protein Name | Sphingosine-1-Phosphate Receptor 1 (S1PR1) |
| Gene | [S1PR1](/genes/s1pr1) |
| UniProt ID | [P21453](https://www.uniprot.org/uniprot/P21453) |
| Molecular Weight | ~43 kDa (382 amino acids) |
| Subcellular Localization | Plasma membrane |
| Protein Family | G protein-coupled receptor family (S1PR1-5) |
| Chromosomal Location | 1p21 |
| Brain Expression | Neurons, astrocytes, microglia, oligodendrocytes |
</div>

Overview

Sphingosine-1-Phosphate Receptor 1 (S1PR1) is a G protein-coupled receptor (GPCR) that binds the bioactive lipid sphingosine-1-phosphate (S1P). S1PR1 is the founding member of a family of five S1P receptors (S1PR1-5) that are widely expressed throughout the body and regulate diverse physiological processes including immune cell trafficking, vascular development, and neural function[@chun2006][@cyster2014].

S1PR1 couples primarily to Gi/o proteins, leading to activation of downstream signaling pathways including PI3K/Akt, MAPK/ERK, and Rac GTPases. This signaling regulates cell survival, proliferation, migration, and cytokine production. In the immune system, S1PR1 is essential for lymphocyte egress from secondary lymphoid organs—a function that underlies the therapeutic efficacy of S1PR1 modulators in multiple sclerosis[@signaling2023].

S1PR1 (Sphingosine-1-Phosphate Receptor 1) Protein

<div class="infobox infobox-protein">
| | |
|---|---|
| Protein Name | Sphingosine-1-Phosphate Receptor 1 (S1PR1) |
| Gene | [S1PR1](/genes/s1pr1) |
| UniProt ID | [P21453](https://www.uniprot.org/uniprot/P21453) |
| Molecular Weight | ~43 kDa (382 amino acids) |
| Subcellular Localization | Plasma membrane |
| Protein Family | G protein-coupled receptor family (S1PR1-5) |
| Chromosomal Location | 1p21 |
| Brain Expression | Neurons, astrocytes, microglia, oligodendrocytes |
</div>

Overview

Sphingosine-1-Phosphate Receptor 1 (S1PR1) is a G protein-coupled receptor (GPCR) that binds the bioactive lipid sphingosine-1-phosphate (S1P). S1PR1 is the founding member of a family of five S1P receptors (S1PR1-5) that are widely expressed throughout the body and regulate diverse physiological processes including immune cell trafficking, vascular development, and neural function[@chun2006][@cyster2014].

S1PR1 couples primarily to Gi/o proteins, leading to activation of downstream signaling pathways including PI3K/Akt, MAPK/ERK, and Rac GTPases. This signaling regulates cell survival, proliferation, migration, and cytokine production. In the immune system, S1PR1 is essential for lymphocyte egress from secondary lymphoid organs—a function that underlies the therapeutic efficacy of S1PR1 modulators in multiple sclerosis[@signaling2023].

In the central nervous system, S1PR1 is expressed on neurons, astrocytes, microglia, and oligodendrocyte progenitor cells. Here it modulates neurogenesis, myelination, synaptic function, and neuroinflammatory responses. S1PR1 modulators like fingolimod (FTY720), siponimod, and ozanimod are approved for treating multiple sclerosis, and extensive research explores their potential in other neurodegenerative conditions[@fty2022][@spr2023].

Gene and Protein Structure

Gene Organization

The human S1PR1 gene is located on chromosome 1p21 and encodes a 382-amino acid protein. The gene consists of 6 exons and is approximately 10 kb in length. The gene is evolutionarily conserved across vertebrates.

Protein Domain Architecture

S1PR1 is a classic GPCR with seven transmembrane helices:

N-terminal Extracellular Domain (aa 1-50): Contains glycosylation sites and contributes to ligand binding pocket. The extracellular loops (ECL1-3) between transmembrane helices also participate in S1P binding.

Transmembrane Domain (aa 51-310): Seven α-helices (TM1-7) connected by intracellular and extracellular loops. This domain contains:

• Conserved GPCR motifs
• Ligand-binding pocket for S1P
• Sites for post-translational modifications

• Phosphorylation sites for receptor desensitization
• G protein coupling sites
• Arrestin binding motifs

Post-translational Modifications

S1PR1 undergoes several modifications:

• N-linked glycosylation: At Asn-16 and other sites, affects folding and trafficking
• Palmitoylation: At cysteine residues near the membrane, affects localization
• Phosphorylation: At serine/threonine residues in the C-terminal tail, mediates desensitization

Normal Physiological Functions

Immune Cell Trafficking

S1PR1's best-characterized function is regulating lymphocyte egress:

Lymphocyte Egress: S1P concentration gradients guide lymphocytes from lymphoid organs into lymph and blood. S1PR1 on mature T and B cells responds to high systemic S1P, enabling their exit.

T Cell Trafficking: Naive T cells express S1PR1 and require it for exit from lymph nodes. Memory T cells use S1PR1 for recirculation.

B Cell Trafficking: B cells also require S1PR1 for follicular exit and subsequent migration.

Dendritic Cell Migration: S1PR1 regulates dendritic cell trafficking to lymph nodes.

Vascular Development

S1PR1 is essential for vascular formation:

Angiogenesis: S1P signaling through S1PR1 promotes blood vessel formation and stabilization.

Vascular Maturation: S1PR1 on endothelial cells interacts with pericytes to stabilize vessels.

Vascular Integrity: S1PR1 maintains endothelial barrier function.

Nervous System Functions

In the CNS, S1PR1 has multiple roles:

Neurogenesis: S1PR1 regulates neural progenitor cell proliferation and migration in the subventricular zone and dentate gyrus.

Myelination: S1PR1 influences oligodendrocyte differentiation and myelination. Both S1P and S1PR1 are required for proper myelin formation.

Synaptic Function: S1PR1 is expressed at synapses and modulates synaptic transmission and plasticity.

Astrocyte Function: S1PR1 regulates astrocyte morphology and function.

Microglial Activation: S1PR1 modulates microglial activation states and neuroinflammatory responses.

Expression and Localization

Brain Regional Distribution

S1PR1 exhibits region-specific expression:

• Cortex: High expression in pyramidal neurons
• Hippocampus: CA1, CA3, dentate gyrus
• Cerebellum: Purkinje cells and granule cells
• White Matter: Oligodendrocyte progenitor cells
• Subventricular Zone: Neural progenitor cells

Cellular and Subcellular Localization

At the cellular level:

• Neurons: Somatic and dendritic membrane localization
• Astrocytes: Throughout astrocyte processes
• Microglia: Punctate pattern consistent with endosomal localization
• Oligodendrocytes: Primarily in progenitor cells and immature oligodendrocytes
• Endothelial Cells: Blood-brain barrier

• Early endosomes (signaling compartments)
• Growth cones in developing neurons
• Synaptic terminals

Role in Multiple Sclerosis

Clinical Evidence

S1PR1 is a validated therapeutic target in multiple sclerosis:

FTY720 (Fingolimod): First oral disease-modifying therapy for MS, approved in 2010. Works primarily through S1PR1 modulation.

Siponimod (BAF312): S1PR1 and S1PR5 selective modulator, approved for secondary progressive MS.

Ozanimod: S1PR1 and S1PR5 selective, approved for relapsing forms of MS.

Ponesimod: S1PR1 selective, approved for relapsing forms of MS.

Mechanisms in MS

S1PR1 modulators work through multiple mechanisms:

Lymphocyte Sequestration: By acting as functional antagonists at S1PR1, these drugs prevent lymphocyte egress from lymph nodes. This reduces autoreactive T and B cells entering the CNS.

Direct CNS Effects: S1PR1 modulators also act on CNS cells:

• Reduce astrocyte activation
• Modulate microglial responses
• May promote oligodendrocyte precursor differentiation
• Protect neurons from inflammatory damage

Therapeutic Outcomes

Clinical trials show:

• Reduced relapse rates (40-50% reduction)
• Slowed disability progression
• Reduced MRI lesion activity
• Brain volume loss reduction

• Cardiovascular effects (bradycardia)
• Macular edema
• Liver enzyme elevations
• Increased infection risk

Role in Alzheimer's Disease

Evidence

S1PR1 alterations have been reported in Alzheimer's disease:

Expression Changes: S1PR1 expression is altered in AD brains, with some studies showing increased expression in affected regions.

Genetic Studies: Some S1PR1 variants have been associated with AD risk, though data are not as extensive as for other genes.

Therapeutic Potential: S1PR1 modulators may have benefits in AD through:

• Reduced neuroinflammation
• Modulation of microglial activation
• Potential effects on amyloid metabolism
• Neuroprotection

Mechanisms

Microglial Modulation: S1PR1 regulates microglial activation states. S1PR1 modulation may shift microglia toward protective phenotypes.

Neuroinflammation: S1PR1 signaling influences inflammatory cytokine production and immune cell infiltration.

Astrogliosis: S1PR1 affects astrocyte reactivity, which is prominent in AD.

Synaptic Function: S1PR1 modulation may protect synapses from inflammatory damage.

Role in Parkinson's Disease

Evidence

Limited evidence links S1PR1 to Parkinson's disease:

Expression Changes: Some studies show altered S1P signaling in PD models and patient tissue.

Therapeutic Potential: S1PR1 modulators may provide benefits through:

• Neuroprotection of dopaminergic neurons
• Reduced neuroinflammation
• Improved mitochondrial function

Mechanisms

Dopaminergic Neuron Survival: S1PR1 signaling promotes neuronal survival in models of dopaminergic degeneration.

Neuroinflammation: S1PR1 modulates microglial activation relevant to PD pathogenesis.

Mitochondrial Function: S1P signaling affects mitochondrial dynamics and function.

Role in Stroke and Ischemia

Evidence

S1PR1 modulation is protective in stroke models:

FTY720 Protection: FTY720 reduces infarct size and improves functional outcomes in animal models of ischemic stroke.

Mechanisms

Anti-inflammatory: Reduced post-ischemic inflammation.

Neuroprotection: Direct protective effects on neurons.

Vascular Effects: May improve blood flow to ischemic penumbra.

Lymphocyte Effects: Reduced infiltration of inflammatory cells.

Interacting Partners

| Partner | Interaction Type | Functional Role |
|---------|-----------------|-----------------|
| S1P (sphingosine-1-phosphate) | Ligand binding | Receptor activation |
| Gi/o proteins | G protein coupling | Signal transduction |
| β-arrestin | Adapter protein | Receptor internalization |
| GRK | Kinase | Phosphorylation/desensitization |
| RGS proteins | GAP activity | Signal termination |
| S1PR5 | Receptor heterodimerization | Functional interaction |

Signaling Pathways

S1PR1 activates multiple downstream cascades:

Gi/o Pathways:

• Inhibition of adenylate cyclase (reduced cAMP)
• Activation of PI3K/Akt (cell survival)
• Activation of MAPK/ERK (proliferation, differentiation)
• Activation of Rac (actin dynamics, migration)

• Receptor internalization
• G protein-independent signaling
• MAPK activation

Animal Models

S1pr1 Knockout Mice

Phenotype: S1pr1⁻/⁻ mice show:

• Embryonic lethality (vascular defects)
• Lymphocyte trafficking defects
• Impaired neurogenesis

Conditional Knockouts

Neural-specific deletion: Show alterations in neurogenesis and myelination.

Astrocyte-specific deletion: Reveal role in astrocyte function.

Disease Models

EAE (MS model): S1PR1 modulators are highly effective.

Stroke models: FTY720 reduces damage.

AD models: Mixed results—some benefit, some concerns.

Therapeutic Targeting

Approved Modulators

Fingolimod (FTY720):

• First-generation S1PR modulator
• Phosphorylated in vivo to active form
• Binds S1PR1, S1PR3, S1PR4, S1PR5
• Used in relapsing-remitting MS

• Selective for S1PR1 and S1PR5
• Better cardiovascular safety profile
• Approved for secondary progressive MS

• S1PR1 and S1PR5 selective
• Used in relapsing forms of MS

• Highly selective for S1PR1
• Once-daily oral dosing

Emerging Strategies

• S1PR1-selective modulators: Reduced off-target effects
• Positive allosteric modulators: Enhance endogenous S1P signaling
• G protein-biased agonists: Different signal bias
• Regional delivery: CNS-targeted approaches

Challenges

• Cardiovascular side effects (bradycardia)
• Immune suppression and infection risk
• Liver toxicity
• Need for cardiac monitoring
• Variable response across patients

Research Methods

Study of S1PR1 employs various approaches:

• Radioligand binding: Characterize ligand affinity
• cAMP assays: Measure G protein signaling
• Cell migration assays: Chemotaxis studies
• Immunohistochemistry: Tissue localization
• Transgenic models: Knockout and knockin mice
• Clinical trials: Human efficacy and safety

Cross-Links

• [S1PR1 Gene](/genes/s1pr1)
• [Sphingosine-1-Phosphate Signaling](/mechanisms/s1p-signaling)
• [Multiple Sclerosis](/diseases/multiple-sclerosis)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Myelination](/mechanisms/myelination)
• [Blood-Brain Barrier](/mechanisms/blood-brain-barrier)

See Also

• [S1P Receptor Family](/mechanisms/s1p-receptor-family)
• [FTY720 Mechanism](/mechanisms/fty720-mechanism)
• [Sphingolipid Signaling](/mechanisms/sphingolipid-signaling)
• [Immunomodulation in MS](/mechanisms/immunomodulation-ms)
• [Neuroprotection](/treatments/neuroprotection)

External Links

• [UniProt: P21453](https://www.uniprot.org/uniprot/P21453)
• [AlphaFold: P21453](https://alphafold.ebi.ac.uk/entry/P21453)
• [GeneCards: S1PR1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=S1PR1)
• [OMIM: 601974](https://omim.org/entry/601974)

References